STOCK TITAN

CIBUS INC - CBUS STOCK NEWS

Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.

Company Overview

Cibus Inc is an agricultural biotechnology company specializing in the development and commercialization of advanced crop traits. Utilizing its proprietary Rapid Trait Development System (RTDS®), the company leverages cutting‐edge gene editing technologies to create and license plant traits that address critical challenges in modern farming. These include improved herbicide tolerance, enhanced disease resistance, optimized weed management, and better nutrient utilization, all of which contribute to increased productivity and sustainable farming practices.

Innovative Technology and Process

Cibus has revolutionized traditional breeding methodologies by introducing a highly efficient, high-throughput system that integrates crop-specific cell biology with sophisticated gene editing tools. The company’s technology allows for multiple gene modifications in a single developmental cycle—significantly reducing the time and cost associated with conventional breeding programs. This capability not only accelerates trait development but also ensures that the resultant genetic modifications are indistinguishable from those produced through natural processes, thereby positioning Cibus distinctively within the agricultural biotechnology landscape.

Business Model and Market Position

Unlike traditional seed companies, Cibus operates as a technology provider. Its core business model centers on developing novel crop traits and licensing them to seed companies, who then incorporate these traits into their breeding programs. This licensing model allows Cibus to generate revenue through royalties on seed sales, aligning its success with the productivity gains achieved by farmers worldwide. Emphasizing its industrialized approach to breeding, Cibus sets rigorous production standards that consistently deliver results in a predictable, time-bound manner.

Product Portfolio and Applications

The company’s robust portfolio includes multiple traits developed for major global row crops such as canola, rice, soybean, and others. Among its innovations are herbicide tolerance traits (such as HT1, HT2, and HT3) that provide farmers with additional tools for combating herbicide-resistant weeds, as well as traits designed to enhance resistance to significant crop diseases like Sclerotinia. These portfolio elements underscore Cibus’ commitment to addressing the productivity and sustainability challenges faced by modern agriculture.

Technological Integration and Collaborations

Cibus continues to push the boundaries of crop trait development through strategic collaborations. By partnering with leaders in artificial intelligence and machine learning, the company enhances its target discovery process, ensuring that its gene-editing efforts are both precise and scalable. These collaborations enable the identification of novel gene targets and streamline the application of complex edits, thereby reinforcing the company’s position as a pioneer in high-throughput gene editing.

Industry Impact and Expertise

Operating at the intersection of biotechnology and agriculture, Cibus provides a vital contribution to the farming sector by addressing issues that traditionally lead to significant economic losses. Through its innovative technology, the company plays a central role in modernizing plant breeding and delivering traits that can alleviate challenges such as pest infestations, plant diseases, and herbicide resistance. The scientific underpinnings of its RTDS® process not only embody a breakthrough in crop improvement but also exemplify the expertise and technical rigor that define Cibus’ approach to sustainable agriculture.

Conclusion

In summary, Cibus Inc stands out for its cutting-edge gene editing technology, streamlined trait development process, and strategic licensing model. Its comprehensive focus on enhancing crop resilience and yield through advanced plant trait innovations makes it a key player in the agricultural biotechnology industry. The company’s commitment to rapidly delivering impactful solutions underscores its potential as an instrumental force in addressing complex agricultural challenges.

Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) has announced successful field trials for its rice herbicide tolerance traits, HT1 and HT3, and its canola Pod Shatter Reduction (PSR) trait. The company is preparing for the commercial launch of these traits, with field scale demonstrations in the US Mid-South and plans to integrate the traits into product lines. Cibus also reported that its PSR trait in canola seed developer genetics performed well, leading to the first hybrid sales as early as 2025. The company aims to change the canola/WOSR market by broadly licensing its PSR trait to seed developers globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) successfully regenerates plants from single cells in a wheat cultivar, representing a major breakthrough for the company and the seed industry. This achievement accelerates trait development in wheat, a key crop for global food security, and demonstrates Cibus' success in developing scalable high throughput breeding platforms for major crops.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) collaborates with Interoc to introduce two herbicide tolerance traits for rice growers in Latin America, aiming to address weed management challenges and improve yields in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs). The proposal aims to regulate NGT products similar to conventional varieties, aligning EU policy with trading partners in North and South America, Australia, India, and Japan. The proposal was adopted by the EU College of Commissioners and is currently under review in committees of the European Parliament and by Ministers of Member States in the Council of the European Union. Members of the European Parliament are expected to vote on the proposal in January 2024, with an adoption date proposed in July 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) has priced an underwritten offering of 2,106,723 shares of its Class A Common Stock and Pre-Funded Warrants to purchase up to 50,000 shares of its Class A Common Stock. The offering price is $9.00 per share, with gross proceeds estimated to be approximately $20.3 million. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) acknowledges the European Union's proposal for the regulation of plants obtained from New Genomic Techniques (NGTs). The proposal aims to bring EU policy closer to that of trading partners in North and South America, Australia, India, and Japan. The proposal is a result of a European Commission study, requested by EU Member States, which concluded that EU GMO legislation was not fit for purpose in relation to applications of NGTs in plants. The proposal, currently under review, describes a category of NGTs producing modifications that could be obtained in nature or by conventional breeding, which would be regulated in the same way as conventional varieties. The proposal is scheduled for adoption in July 2024, with additional implementing acts required to be passed within 24 months for the new legislation to become fully operational.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
none
Rhea-AI Summary
Cibus, Inc. (NASDAQ: CBUS) has announced the publication of a paper in the International Journal of Plant Biology, showcasing case studies of improving oleic oil content and developing pod shatter reduction in Brassica napus using gene editing tools on an industrial scale. The company's Trait Machine™ System has led to breakthroughs in breeding and scale, reducing timelines to develop new traits from as much as 16 years to approximately three to five years. Cibus is driving the speed and number of edited seed transfers of its pod shatter reduction trait to major seed company customers, with increased throughput allowing delivery of multiple elite genetic lines integrating into advanced commercial breeding programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) announced its financial results for the quarter ended September 30, 2023, and provided a business update. The company completed extensive field trials for its PSR trait in canola and HT1 and HT3 in rice. It also reported continued progress of its high-throughput soybean editing system and two advanced traits for Sclerotinia resistance and HT2. Cibus launched strategic realignment and cost savings initiatives to focus on advancing late-stage activities. Initial UK field trials for its PSR trait in WOSR are underway, and the company is accelerating its PSR trait in the European market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.76%
Tags
-
Rhea-AI Summary
Cibus, Inc. supports the European Commission's proposal to regulate plants obtained from new genomic techniques (NGTs) and their food and feed. The proposed regulation introduces a 'Conventional-like' category for NGT products, aligning EU policy with trading partners in North and South America, Australia, and Japan. The report highlights the potential of NGTs to enhance agriculture and food production in Europe. Cibus' gene editing platform products, such as disease-resistant canola and oilseed rape with reduced seed losses, would fall under the 'Conventional-like' category.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) will report its third quarter 2023 financial results on November 9, 2023. The company's management team will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and other company updates. Interested individuals can access a dial-in replay of the call or a live audio webcast with accompanying slides on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences earnings

FAQ

What is the current stock price of CIBUS (CBUS)?

The current stock price of CIBUS (CBUS) is $2.26 as of March 13, 2025.

What is the market cap of CIBUS (CBUS)?

The market cap of CIBUS (CBUS) is approximately 78.5M.

What is the primary focus of Cibus Inc?

Cibus Inc focuses on developing and commercializing advanced crop traits through proprietary gene editing technology, addressing key challenges in modern agriculture.

How does Cibus generate revenue?

The company licenses its innovative crop traits to seed companies, earning royalties based on the commercial success of these traits integrated into agricultural products.

What is the Rapid Trait Development System (RTDS®)?

RTDS® is Cibus Inc's proprietary, high-throughput platform that accelerates the development of plant traits by making multiple gene edits in a single process, reducing both time and cost.

How is Cibus' gene editing approach different from conventional methods?

Unlike traditional breeding methods, Cibus uses gene editing to create traits that are indistinguishable from naturally developed traits, enabling faster and more predictable outcomes without the complexities of GMO products.

What types of crop traits does Cibus develop?

Cibus develops a wide range of traits, including herbicide tolerance, disease resistance, and traits for improved weed management that are applicable to major row crops such as canola, rice, and soybean.

Does Cibus manufacture seeds directly?

No, Cibus is not a seed company. It functions as a technology provider by developing crop traits and licensing them to seed companies, which in turn incorporate these traits into their products.

How do Cibus’ partnerships contribute to its innovation?

Strategic collaborations, including those with AI and machine learning firms, enhance Cibus’ gene discovery and editing processes, allowing for more precise and scalable crop trait development.

What benefits do seed companies gain from using Cibus’ traits?

Seed companies benefit from the rapid development, predictability, and enhanced performance of Cibus’ traits, which can improve crop yield, resistance to pests and diseases, and overall agronomic performance.
CIBUS INC

Nasdaq:CBUS

CBUS Rankings

CBUS Stock Data

78.53M
23.17M
25.33%
28.97%
8.72%
Biotechnology
Agricultural Chemicals
Link
United States
SAN DIEGO